Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Area of Science:

• Cardiovascular medicine
• Pharmacogenetics
• Genomics

Background:

• Cardiovascular diseases (CVs) are a leading cause of global mortality and disability.
• While drug treatments have improved outcomes, adverse events remain a significant challenge.
• Pharmacogenetics offers a pathway to personalize cardiovascular pharmacotherapy, minimizing toxicity and enhancing efficacy.

Purpose of the Study:

• To compile, compare, and discuss international pharmacogenetics guidelines for cardiovascular pharmacotherapy.
• To analyze recommendations from major consortia like CPIC, DPWG, RNPGx, and CPNDS.
• To evaluate pharmacogenetic information in drug labels and major cardiology treatment guidelines (ESC, ACC, AHA).

Main Methods:

• Systematic review and comparative analysis of published pharmacogenetic guidelines and recommendations.
• Inclusion of guidelines from key international pharmacogenetics consortia.
• Assessment of pharmacogenetic information within drug labels and major cardiovascular society guidelines.

Main Results:

• Significant variability exists in pharmacogenetic recommendations across different guidelines, impacting clinical applicability.
• Key pharmacogenetic consortia provide gene-drug pair recommendations for cardiovascular medications.
• Drug labels and cardiology guidelines increasingly incorporate pharmacogenetic insights, though consensus is evolving.

Conclusions:

• Harmonizing pharmacogenetic guidelines is crucial for widespread clinical adoption in cardiology.
• Pharmacogenetics holds significant potential to optimize cardiovascular drug therapy and improve patient outcomes.
• Further research and guideline development are needed to standardize the application of pharmacogenetics in cardiovascular medicine.